26 Aug BioTechnique Begins Phase 2 of Partnership
BioTechnique, a specialty drug aseptic fill-finish contract manufacturing organization, will launch a second phase of manufacturing in partnership with a major, international not-for-profit organization, the company announced recently.
“We are very pleased to support a major non-profit trust in bringing their novel dosage form to market,” BioTechnique CEO John Clapham said in a statement. “With the continuation of this live attenuated virus manufacturing partnership, we have broadened our ability meet demand from our customers who need a reliable contract manufacturing partner.”
Sorry, the comment form is closed at this time.